Free Trial
NASDAQ:ABVC

ABVC BioPharma Q3 2025 Earnings Results & Report

ABVC BioPharma logo
$0.94 +0.03 (+3.30%)
As of 03:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ABVC BioPharma reported Q3 2025 earnings on October 31, 2025. The company reported EPS of -$0.05, while revenue was $795.95 thousand.

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
After Market Closes
Conference Call Date
Conference Call
7:30 AM ET

ABVC BioPharma EPS Results

Actual EPS
-$0.05
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ABVC BioPharma Revenue Results

Actual Revenue
$795.95 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ABVC BioPharma Q3 2025 Earnings FAQ

ABVC BioPharma (NASDAQ:ABVC) reported earnings of -$0.05 per share for Q3 2025. The report was announced on Friday, October 31, 2025.

ABVC BioPharma reported revenue of $795.95 thousand for Q3 2025.

ABVC BioPharma Earnings Headlines

/C O R R E C T I O N - WallachBeth Capital LLC/
I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
ABVC BioPharma Delays Quarterly SEC Filing
See More ABVC BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ABVC BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ABVC BioPharma and other key companies, straight to your email.

About ABVC BioPharma

ABVC BioPharma (NASDAQ:ABVC) is a clinical-stage biopharmaceutical company focused on developing botanical drug candidates and medical devices. The company conducts research and development through its subsidiaries and external partners.

Its pipeline includes ABV-1504, a botanical drug candidate being developed for major depressive disorder, and ABV-1505, a candidate for attention-deficit/hyperactivity disorder. These products remain in development and are not described as approved treatments.

Founded in 2015 and headquartered in Fremont, California, ABVC also pursues development opportunities in oncology and other therapeutic areas. Its work includes collaborations and licensing arrangements to advance its product candidates.

View ABVC BioPharma Profile